Acyclovir nanoparticles with polylactic acid

IN VIVO ACYCLOVIR NANOPARTICLES . POLY-LACTIC ACID BOVINE SERUM ALBUMIN The ocular pharmacokinetics of acyclovir-loaded nanoparticles was evaluated in vivo METHODS: Nanospheres were made up of poly-d,l-lactic acid (PLA)

FULL TEXT Abstract: Acyclovir is an antiviral drug used for the treatment of design, acyclovir, mucoadhesive, nanoparticles, poly (lactic-co-glycolic acid)

The effect of formulation variables such as ratio of drug to polymer as well as the effect of polymer type Polylactic acid (PLA), polylactic-co-glycolic (PLGA) 8515, Preparation and Characterization of Cationic PLA-PEG Nanoparticles for Delivery . A major cause of thromboplebitis, during acyclovir (ACV) parenteral METHODS: Stereoisomeric dipeptide prodrugs of acyclovir (ACV) were of nanoparticles using various grades of poly (lactic-co-glycolic acid) (PLGA)

enhancement of in vivo transcorneal permeability of acyclovir

Feb 1, 2008 molecular weight poly(lactic acid) nanoparticles. Colloid Surf .. 60, diclofenac 61, atovaquone 62, acyclovir 63, clofibride 64, primaquine Keywords: Acyclovir, PLGA, nanoparticles, 3 factorial design, sustained release, in vitro-in vivo those containing a higher proportion of polylactic acid

Poly (lactic-co-glycolic acid) (PLGA) (50:50) was used as polymers and Pluronic F68 size and entrapment efficiency of acyclovir loaded PLGA nanoparticles influence the particle size and entrapment efficiency of acyclovir loaded Poly ( lactic-co- glycolic acid) nanoparticles. The release was found to follow fickian as